SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Anna S.F. Lok, Brian J. McMahon, Robert S. Brown, John B. Wong, Ahmed T. Ahmed, Wigdan Farah, Jehad Almasri, Fares Alahdab, Khalid Benkhadra, Mohamed A. Mouchli, Siddharth Singh, Essa A. Mohamed, Abd Moain Abu Dabrh, Larry J. Prokop, Zhen Wang, Mohammad Hassan Murad, Khaled Mohammed, Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis, Hepatology, 2016, 63, 1
  2. 2
    Mi Na Kim, Kwang-Hyub Han, Sang Hoon Ahn, Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination, Seminars in Oncology, 2015, 42, 2, 316

    CrossRef

  3. You have free access to this content3
    Michela Triolo, Cristina Della Corte, Massimo Colombo, Impact of HBV therapy on the incidence of hepatocellular carcinoma, Liver International, 2014, 34,
  4. You have free access to this content4
    JSH Guidelines for the Management of Hepatitis B Virus Infection, Hepatology Research, 2014, 44,
  5. 5
    Ching-Lung Lai, Man-Fung Yuen, Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy, Hepatology, 2013, 57, 1
  6. You have free access to this content6
    Soji Shimomura, Shuhei Nishiguchi, Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection, Hepatology Research, 2012, 42, 1
  7. 7
    Hui Jin, Ning Pan, Yi Mou, Bei Wang, Pei Liu, Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression, Hepatology Research, 2011, 41, 6
  8. You have free access to this content8
    W. S. Ayoub, E. B. Keeffe, Review article: current antiviral therapy of chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2011, 34, 10
  9. 9
    David W. Hutton, Samuel K. So, Margaret L. Brandeau, Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China, Hepatology, 2010, 51, 2
  10. 10
    Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Kenneth Kar-Lung Yan, Angel Mei-Ling Chim, Hoi-Yun Chan, Chi-Hang Tse, Paul Cheung-Lung Choi, Anthony Wing-Hung Chan, Joseph Jao-Yiu Sung, Henry Lik-Yuen Chan, Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B, Hepatology, 2010, 51, 6
  11. 11
    Yong-Feng Yang, Wei Zhao, Hai-Ming Xia, Yan-Dan Zhong, Ping Huang, Jian Wen, Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: A meta-analysis, Antiviral Research, 2010, 85, 2, 361

    CrossRef

  12. 12
    G. L.-H. Wong, K. K.-L. Yiu, V. W.-S. Wong, K. K.-F. Tsoi, H. L.-Y. Chan, Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2010, 32, 9
  13. 13
    R. Moucari, P. Marcellin, Négativation de l’antigène HBs : valeur pronostique pour la réponse au traitement et l’évolution à long terme, Gastroentérologie Clinique et Biologique, 2010, 34, S119

    CrossRef

  14. 14
    T. Asselah, O. Lada, P. Marcellin, Résultats des essais thérapeutiques dans l’hépatite chronique B, Antibiotiques, 2010, 12, 1, 42

    CrossRef

  15. 15
    Harry L.A. Janssen, Erik H.C.J. Buster, Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy, Journal of Hepatology, 2009, 51, 1, 224

    CrossRef

  16. 16
    Erik H C J Buster, Hajo J Flink, Halis Simsek, E Jenny Heathcote, Sachithanandan Sharmila, George E Kitis, Guido Gerken, Maria Buti, Richard A de Vries, Elke Verhey, Bettina E Hansen, Harry L A Janssen, Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients, The American Journal of Gastroenterology, 2009, 104, 10, 2449

    CrossRef

  17. 17
    Catherine T Frenette, Robert G Gish, Editorial: To “Be” or Not to “Be”: That Is the Question, The American Journal of Gastroenterology, 2009, 104, 8, 1948

    CrossRef

  18. 18
    Erik H.C.J. Buster, Bettina E. Hansen, George K.K. Lau, Teerha Piratvisuth, Stefan Zeuzem, Ewout W. Steyerberg, Harry L.A. Janssen, Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa, Gastroenterology, 2009, 137, 6, 2002

    CrossRef

  19. 19
    T. Poynard, J. Massard, M. Rudler, A. Varaud, P. Lebray, J. Moussalli, M. Munteanu, Y. Ngo, D. Thabut, Y. Benhamou, V. Ratziu, Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials, Gastroentérologie Clinique et Biologique, 2009, 33, 10-11, 916

    CrossRef

  20. 20
    Y.-F. Yang, W. Zhao, Y.-D. Zhong, H.-M. Xia, L. Shen, N. Zhang, Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis, Journal of Viral Hepatitis, 2009, 16, 4
  21. 21
    J. J. Y. SUNG, K. K. F. TSOI, V. W. S. WONG, K. C. T. LI, H. L. Y. CHAN, Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, 2008, 28, 9
  22. 22
    Erik H.C.J. Buster, Solko W. Schalm, Harry L.A. Janssen, Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1093

    CrossRef

  23. 23
    Teerha Piratvisuth, Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B, Hepatology International, 2008, 2, 2, 140

    CrossRef

  24. 24
    Erik H.C.J. Buster, Hajo J. Flink, Yilmaz Cakaloglu, Krzysztof Simon, Jörg Trojan, Fehmi Tabak, Thomas M.K. So, S. Victor Feinman, Tomasz Mach, Ulus S. Akarca, Martin Schutten, Wanda Tielemans, Anneke J. van Vuuren, Bettina E. Hansen, Harry L.A. Janssen, Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b, Gastroenterology, 2008, 135, 2, 459

    CrossRef

  25. 25
    I-Chin Wu, Mitchell L. Shiffman, Myron J. Tong, Patrick Marcellin, Elsa Mondou, David Frederick, Andrea Snow-Lampart, Jeff Sorbel, Franck Rousseau, Ting-Tsung Chang, Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants, Clinical Infectious Diseases, 2008, 47, 10, 1305

    CrossRef

  26. 26
    T. Asselah, O. Lada, N. Boyer, M. Martinot, P. Marcellin, Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 749

    CrossRef

  27. 27
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  28. 28
    C. A. Benson, J. E. Kaplan, H. Masur, A. Pau, K. K. Holmes, Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America, Clinical Infectious Diseases, 2005, 40, Supplement 3, S131

    CrossRef

  29. 29
    Emmet B. Keeffe, Douglas T. Dieterich, Steve-huy B. Han, Ira M. Jacobson, Paul Martin, Eugene R. Schiff, Hillel Tobias, Teresa L. Wright, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States, Clinical Gastroenterology and Hepatology, 2004, 2, 2, 87

    CrossRef

  30. 30
    Peter Karayiannis, Current therapies for chronic hepatitis B virus infection, Expert Review of Anti-infective Therapy, 2004, 2, 5, 745

    CrossRef

  31. 31
    Chloe L. Thio, Hepatitis B virus infection in HIV-infected persons, Current Hepatitis Reports, 2004, 3, 3, 91

    CrossRef

  32. 32
    Monika van Zonneveld, Pieter Honkoop, Bettina E. Hansen, Hubertus G.M. Niesters, Sarwa Darwish Murad, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B, Hepatology, 2004, 39, 3
  33. 33
    ROBERT YM CHEN, PAUL V DESMOND, STEPHEN A LOCARNINI, Emerging therapies of hepatitis B and C, Journal of Gastroenterology and Hepatology, 2002, 17,
  34. 34
    STEVEN CROWLEY, DAVID TOGNARINI, PAUL DESMOND, MICHAEL LEES, GAURI SAAL, Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data, Journal of Gastroenterology and Hepatology, 2002, 17, 2
  35. 35
    Ewa Orlewska, The Cost-Effectiveness of Alternative Therapeutic Strategies for the Management of Chronic Hepatitis B in Poland, Value in Health, 2002, 5, 5, 405

    CrossRef

  36. 36
    Y.-F. Liaw, Therapy of chronic hepatitis B: current challenges and opportunities, Journal of Viral Hepatitis, 2002, 9, 6
  37. 37
    A.B van Nunen, H.L.A Janssen, L.M.M Wolters, H.G.M Niesters, R.A de Man, S.W Schalm, Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?, Antiviral Research, 2001, 52, 2, 139

    CrossRef

  38. 38
    M. Lindh, C. Hannoun, P. Horal, K. Krogsgaard, Virological response to interferon therapy of chronic hepatitis B as measured by a highly sensitive assay, Journal of Viral Hepatitis, 2001, 8, 5
  39. 39
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,